-
41.发明授权
公开(公告)号：EP2057187B1
公开(公告)日：2016-12-28
申请号：EP07805938.3
申请日：2007-08-10
IPC分类号： C07K14/43
CPC分类号： C07K16/18 , A61K31/7088 , C07K14/47 , C07K14/4748 , C12N2310/14 , C12Q1/485 , G01N33/5011 , G01N33/5035 , G01N33/57415 , G01N2333/9121 , G01N2510/00
-
公开(公告)号：EP2044123B1
公开(公告)日：2013-03-13
申请号：EP06783136.2
申请日：2006-08-24
发明人： NAKAMURA, Yusuke , KATAGIRI, Toyomasa , NAKATSURU, Shuichi , ENDO, Keigo , KUHARA, Motoki , YAGI, Kasumi
IPC分类号： C07K16/30 , A61K39/395
CPC分类号： C07K16/30 , A61K49/0002 , A61K49/0021 , A61K49/0041 , A61K49/0058 , A61K51/1027 , A61K2039/505 , C07K16/2896 , C07K2317/24 , G01N33/57407 , G01N33/57419 , G01N33/57426 , G01N33/57446
-
公开(公告)号：EP1907582B1
公开(公告)日：2012-01-04
申请号：EP06782211.4
申请日：2006-07-26
IPC分类号： C12N15/113 , A61K48/00
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , Y10T436/25
摘要： In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, a Homo sapiens epithelial cell transforming sequence 2 oncogene (ECT2) and a cell division cycle 45, S. cerevisiae, homolog-like (CDC45L) are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer. Furthermore, the present inventors have identified DKK1 as a potential biomarker for diagnosis of cancer such as lung and esophageal cancers as well as prediction of the poor prognosis of the patients with these diseases. DKK1 was specifically over-expressed in most lung and esophageal cancer tissues the present inventors examined, and was elevated in the sera of a large proportion of patients with these tumors. DKK1, combined with other tumor markers, could significantly improve the sensitivity of cancer diagnosis. Moreover, this molecule is also a likely candidate for development of therapeutic approaches such as antibody therapy.
-
公开(公告)号：EP1737979B9
公开(公告)日：2011-09-21
申请号：EP05721540.2
申请日：2005-03-18
IPC分类号： C12Q1/68
CPC分类号： A61K31/731 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
-
公开(公告)号：EP1853703B1
公开(公告)日：2011-04-13
申请号：EP06714493.1
申请日：2006-02-17
CPC分类号： C12N9/1211 , C12Q1/6886
摘要： The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.
-
公开(公告)号：EP1737979B1
公开(公告)日：2011-01-19
申请号：EP05721540.2
申请日：2005-03-18
IPC分类号： C12Q1/68
CPC分类号： A61K31/731 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.
摘要翻译： 公开了使用差异表达基因KIF11，GHSR1b，NTSR1和FOXM1检测非小细胞肺癌（NSCLC）的方法。 还公开了基于KOC1和KIF11或NMU和GHSR1b或NTSR1之间的相互作用鉴定用于治疗和预防NSCLC的化合物的方法。
-
公开(公告)号：EP2262541A1
公开(公告)日：2010-12-22
申请号：EP09718793.4
申请日：2009-03-10
IPC分类号： A61K49/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P35/00 , C07K16/18 , C12N15/09 , C12Q1/02 , G01N33/15 , G01N33/50
CPC分类号： G01N33/57438 , A61K48/005 , C07K16/303 , C12N15/113 , C12N2310/14 , G01N2500/02
摘要： Described herein are objective methods for detecting or diagnosing a predisposition to developing cancer, particularly pancreatic cancer. In one embodiment, the diagnostic method involves the step of determining an expression level of C2orf18 using anti-C2orf18 antibody. The present invention further provides methods of screening for therapeutic agents useful in the treatment of a C2orf18-associated disease, such as a cancer, e.g. pancreatic cancer, methods of inhibiting the cell growth and treating or alleviating their symptom. The invention also features products, such as polynucleotides, polypeptides, and vectors double-stranded molecules, antibodies, vectors and compositions composed thereof.
-
48.发明公开
公开(公告)号：EP2059593A2
公开(公告)日：2009-05-20
申请号：EP07792516.2
申请日：2007-08-08
IPC分类号： C12N15/11 , A61K31/7088 , A61K39/395 , C07K16/32 , C07K14/475 , A61K38/00 , A61P35/00 , C12Q1/68 , G01N33/53
CPC分类号： C12N15/1135 , A61K38/00 , C07K14/47 , C07K16/18 , C07K2317/56 , C07K2317/565 , C12N2310/111 , C12N2310/14 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of an siRNA that inhibits expression of REG4 or KIAA0101. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumor cell, for example pancreatic cancer cell, prostatic cancer cell, breast cancer cell, and bladder cancer cell, particularly pancreatic ductal adenocarcinoma (PDAC) by inhibiting REG4 gene. The present invention also relates to methods of treating or preventing PDAC in a subject comprising the step of administering to said subject a pharmaceutically effective amount of an antibody or fragment thereof that binds to a protein encoded by REG4. The present invention also relates to methods of diagnosing chemo-radiation therapeutic resistance of a cancer. The present invention also provides therapeutic agents or methods for treating cancer using the polypeptides. The polypeptides of the present invention are composed of an amino acid sequence which comprises polypeptide which comprises QKGIGEFF/SEQ ID NO: 21. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine.
-
公开(公告)号：EP2057187A2
公开(公告)日：2009-05-13
申请号：EP07805938.3
申请日：2007-08-10
IPC分类号： C07K14/43
CPC分类号： C07K16/18 , A61K31/7088 , C07K14/47 , C07K14/4748 , C12N2310/14 , C12Q1/485 , G01N33/5011 , G01N33/5035 , G01N33/57415 , G01N2333/9121 , G01N2510/00
摘要： The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.
-
50.发明公开NMU-GHSR1b/NTSR1 ONCOGENIC SIGNALING PATHWAY AS A THERAPEUTIC TARGET FOR LUNG CANCER 审中-公开NMU GHSR1B / NTSR1癌基因，信号作为治疗目标为肺癌
公开(公告)号：EP2018440A1
公开(公告)日：2009-01-28
申请号：EP07742328.3
申请日：2007-04-18
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/178
摘要： The present invention relates to a method of and a kit for assessing the prognosis of lung cancer by detecting the expression level of the neuromedin U (NMU) gene in a patient-derived biological sample. The method and kit are particularly preferred for assessing the prognosis of non-small cell lung cancer (NSCLC). Furthermore, the present invention relates to a method of screening for a therapeutic agent for cancer, in particular, lung cancer, by detecting compounds that inhibit the binding of the NMU protein with the heterodimer of growth hormone secretagogue receptor 1b (GHSR1b) and neurotensin receptor 1 (NTSR1).
-
-
-
-
-
-
-
-
-
搜索结果
54 条记录 (耗时 0.055 秒)
